Skip to main content
SpringerLink
Log in

Imaging of Brain Amyloid Load in Early Alzheimer’s Disease

  • Protocol
  • First Online:
Biomarkers for Preclinical Alzheimer’s Disease

Part of the book series: Neuromethods ((NM,volume 137))

  • 1008 Accesses

Abstract

The content of this chapter deals with the usefulness and indications of amyloid PET for the diagnosis of patients with Alzheimer’s disease (AD). In addition to a description of amyloid PET itself, topics such as early and differential diagnosis of AD are discussed. Measuring amyloid in CSF as an alternative method to amyloid PET and the associations between cerebral amyloid load and the apolipoprotein E genotype are also covered in this section.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 59.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Jansen WJ, Ossenkoppele R, Knol DL et al (2015) Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313:1924–1938

    Article  PubMed  PubMed Central  Google Scholar 

  2. Braak H, .Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259

    Article  CAS  PubMed  Google Scholar 

  3. Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of Aß-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800

    Article  PubMed  Google Scholar 

  4. Grimmer T, Tholen S, Yousefi BH et al (2010) Progression of cerebral amyloid load is associated with the apolipoprotein E epsilon4 genotype in Alzheimer’s disease. Biol Psychiatry 68:879–884

    Google Scholar 

  5. Klunk WE, Engler H, Nordberg A et al (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 55:306–319

    Article  CAS  PubMed  Google Scholar 

  6. Ikonomovic MD, Klunk WE, Abrahamson EE et al (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain 131:1630–1645

    Article  PubMed  PubMed Central  Google Scholar 

  7. Grimmer T, Drzezga A, Kurz A (2010) Visualization of amyloid with positron emission tomography. Useful improvement in the diagnosis of dementia? Nervenarzt 81:602–606

    Article  CAS  PubMed  Google Scholar 

  8. Brun A, Englund B, Gustafson L et al (1994) Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry 57:416–418

    Article  Google Scholar 

  9. Drzezga A, Grimmer T, Henriksen G et al (2008) Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease. Neuroimage 39:619–633

    Article  PubMed  Google Scholar 

  10. Engler H, Santillo AF, Wang SX et al (2008) In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging 35:100–106

    Article  PubMed  Google Scholar 

  11. McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872

    Article  CAS  PubMed  Google Scholar 

  12. Ossenkoppele R, Jansen WJ, Rabinovici GD et al (2015) Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 313:1939–1949

    Article  PubMed  PubMed Central  Google Scholar 

  13. Bateman RJ, Xiong C, Benzinger TL et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367:795–804

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Blendon RJ, Benson JM, Wikler EM et al (2012) The impact of experience with a family member with Alzheimer’s disease on views about the disease across five countries. Int J Alzheimers Dis 2012:903645

    PubMed  PubMed Central  Google Scholar 

  15. Johnson KA, Minoshima S, Bohnen NI et al (2013) Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. J Nucl Med 54:476–490

    Article  CAS  PubMed  Google Scholar 

  16. Barthel, H., Meyer, P. T., Drzezga, A., Bartenstein, P., Boecker, H., Brust, P., Buchert, R., Coenen, H. H., La Fourgère, C., Gründer, G., Grünwald, F., Krause, B. J., Kuwert, T., Schreckenberger, M., Tatsch, K., Langen, K. J., and Sabri, O. (2015) Beta-amyloid-PET-Bildgebung des Gehirns – DGN-Handlungsempfehlung (S1-Leitlinie). www.awmf.org/uploads/tx_szleitlinien/031-052l_S1_Beta_Amyloid-PET-Bildgebung_Gehirn_2016-02.pdf

  17. Minoshima S, Drzezga AE, Barthel H et al (2016) SNMMI procedure standard/EANM practice guideline for amyloid PET imaging of the brain 1.0. J Nucl Med 57:1316–1322

    Article  CAS  PubMed  Google Scholar 

  18. Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde DGPPN and Deutsche Gesellschaft für Neurologie (DGN) (2016) S3-Leitlinie “Demenzen”. https://www.dgppn.de/fileadmin/user_upload/_medien/download/pdf/kurzversion-leitlinien/REV_S3-leiltlinie-demenzen.pdf

  19. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202008s000lbl.pdf. 18 Apr 2017

  20. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203137s005lbl.pdf. 18 Apr 2017

  21. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204677s000lbl.pdf. 18 Apr 2017

  22. Landau SM, Breault C, Joshi AD et al (2013) Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med 54:70–77

    Article  CAS  PubMed  Google Scholar 

  23. Vandenberghe R, Van Laere K, Ivanoiu A et al (2010) 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 68:319–329

    Article  PubMed  Google Scholar 

  24. Villemagne VL, Mulligan RS, Pejoska S et al (2012) Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer’s disease. Eur J Nucl Med Mol Imaging 39:983–989

    Article  CAS  PubMed  Google Scholar 

  25. Grimmer T, Henriksen G, Wester HJ et al (2009) Pittsburgh Compound B(PIB) uptake in positron emission tomography is associated with clinical severity of Alzheimer’s disease. Neurobiol Aging 30(12):1902–1909

    Google Scholar 

  26. Lopresti BJ, Klunk WE, Mathis CA et al (2005) Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 46:1959–1972

    CAS  PubMed  Google Scholar 

  27. Friston KJ, Holmes AP, Worsley KJ (1994) Statistical parametric mapping in functional imaging: a general linear approach. Hum Brain Mapp 2:189–210

    Article  Google Scholar 

  28. Ziolko SK, Weissfeld LA, Klunk WE et al (2006) Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer’s disease. Neuroimage 33:94–102

    Article  PubMed  Google Scholar 

  29. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE (1995) A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 36:1238–1248

    CAS  PubMed  Google Scholar 

  30. Grimmer T, Wutz C, Alexopoulos P et al (2016) Visual versus fully automated analyses of 18F-FDG and amyloid PET for prediction of dementia due to Alzheimer disease in mild cognitive impairment. J Nucl Med 57:204–207

    Article  CAS  PubMed  Google Scholar 

  31. Palmqvist S, Mattsson N, Hansson O (2016) Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography. Brain 139:1226–1236

    Article  PubMed  PubMed Central  Google Scholar 

  32. Fagan AM, Mintun MA, Shah AR et al (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer’s disease. EMBO Mol Med 1:371–380

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Mattsson N, Insel PS, Landau S et al (2014) Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer’s disease. Ann Clin Transl Neurol 1:534–543

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Grimmer T, Riemenschneider M, Forstl H et al (2009) Beta amyloid in Alzheimer’s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 65:927–934

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Drzezga A, Grimmer T, Henriksen G et al (2009) Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 72:1487–1494

    Article  CAS  PubMed  Google Scholar 

  36. Cosentino S, Scarmeas N, Helzner E et al (2008) APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology 70:1842–1849

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Deane R, Sagare A, Hamm K et al (2008) apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 118:4002–4013

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Craft S, Teri L, Edland SD et al (1998) Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer’s disease. Neurology 51:149–153

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Cognitive Disorders, Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany

    Timo Grimmer

  2. Ludwig-Maximilians-University Munich, Munich, Germany

    Jennifer Grace Perryman

Authors
  1. Timo Grimmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer Grace Perryman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timo Grimmer .

Editor information

Editors and Affiliations

  1. Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität München, Munich, Germany

    Robert Perneczky

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media, LLC

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Grimmer, T., Perryman, J.G. (2018). Imaging of Brain Amyloid Load in Early Alzheimer’s Disease. In: Perneczky, R. (eds) Biomarkers for Preclinical Alzheimer’s Disease. Neuromethods, vol 137. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7674-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7674-4_9

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7673-7

  • Online ISBN: 978-1-4939-7674-4

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation